Professional · Issue 4 · 2026-10-15
Next-Generation CFTR Modulator Reaches Preschool-Aged Children with Encouraging Safety and Sweat Chloride Data
Editorially reviewed research summaries, context, and limitations.
Jonathan H Rayment, Gwyneth Davies, Jonathan M Gaffin, et al.
Summary: The TIMBERLINE phase 3 open-label study evaluated vanzacaftor-tezacaftor-deutivacaftor (vanza-teza-deuti) in 67 children aged 2–5 years with ETI-responsive genotypes over 24 weeks. The primary endpoint of safety and tolerability was met, with no treatment-related serious adverse events and no discontinuations. Transitioning from elexacaftor-tezacaftor-ivacaftor (ETI), children achieved a further mean sweat chloride reduction of 9.6 mmol/L, with 65% reaching concentrations below 30 mmol/L.
Why it matters: Extending effective CFTR modulation to preschool-aged children is clinically meaningful because early intervention may limit cumulative lung damage and systemic complications that accrue before school age. Vanza-teza-deuti has already demonstrated superiority over ETI in older cohorts, and these findings suggest the incremental benefit extends to the youngest treatable patients. Given the rarity of this population and the practical challenges of conducting trials in toddlers, this dataset — though small — represents a meaningful advance in the regulatory pathway for label expansion.
Expert perspective: The study is appropriately designed for its developmental stage: a single-arm, open-label phase 3 trial is a defensible and pragmatic choice in a small pediatric population where placebo-controlled designs raise ethical and logistical barriers. The 100% completion rate across 67 children is reassuring, though the open-label design and short 24-week follow-up limit conclusions about long-term safety and functional pulmonary outcomes — spirometry is not reliably measurable in this age group. Using ETI as the active baseline rather than placebo is methodologically sensible but means the incremental benefit of approximately 9.6 mmol/L sweat chloride reduction is measured against an already highly effective therapy, making absolute effect size modest. The 65% achieving sweat chloride below 30 mmol/L is clinically notable, though the long-term significance of this threshold in preschoolers remains incompletely characterized. Vertex funding warrants standard scrutiny, though the trial registration, multicenter design across nine countries, and publication in Lancet Respiratory Medicine provide reasonable confidence in data integrity. Longer follow-up and functional endpoints remain the critical next step.
Relevance: Cystic Fibrosis
Source: https://pubmed.ncbi.nlm.nih.gov/42710511/
---